RADXNasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as RDPTF
Radiopharm Theranostics Ltd
Financials through fiscal 2025, year ended Jun 30, 2025Last filing: 20-F on Sep 30, 2026
$0.96−0.07 (-6.50%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
51M
Shares held, 13F filers
Institutional holders
7
1 new, 1 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Lantheus Holdings, Inc. | 792,958,513 | 17.30% | 13G (passive) | Jul 28, 2026 |
| Lantheus Omega, LLC | 792,958,513 | 20.90% | 13D (active) | Nov 27, 2024 |
| Regal Partners Holdings Pty Limited | 320,694,680 | 9.05% | 13G (passive) | Dec 31, 2025 |
| Regal Funds Management Pty Limited | 172,634,988 | 7.30% | 13G (passive) | Jun 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of RADX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Stonepine Capital Management, LLC | 51,000,000 | – | $670.50K | – | 0.38% |
| Hsbc Holdings PLC | 62,188 | – | $253.73K | +816 | 0.00% |
| Regal Partners Ltd | 40,138 | – | $168.18K | – | 0.01% |
| PNC Financial Services Group, Inc. | 20,000 | – | $83.80K | +4,000 | 0.00% |
| UBS Group AG | 1,507 | – | $6.31K | −1,493 | 0.00% |
| Integrated Wealth Concepts LLC | 1,310 | – | $5.49K | New | 0.00% |
| Rhumbline Advisers | 195 | – | $817 | +74 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|
| Q2 2026 | 7 | 51M | 1 / 3 | 1 / 1 | 0M | 0M |
| Q1 2026 | 7 | 51M | 0 / 1 | 3 / 4 | 0M | 0M |
| Q4 2025 | 11 | 52M | 7 / 0 | 1 / 0 | 51M | 0M |
| Q3 2025 | 4 | 0M | 0 / 2 | 0 / 1 | 0M | 0M |
| Q2 2025 | 5 | 0M | 2 / 0 | 1 / 0 | 0M | 0M |
| Q1 2025 | 3 | 0M | 0 / 0 | 1 / 1 | 0M | 0M |
| Q4 2024 | 4 | 0M | 4 / 0 | 0 / 0 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Riccardo Canevari | Managing Director and CEO | 22,679,986 | Mar 31, 2026 |
| Dimitris Voliotis | Chief Medical Officer | – | May 6, 2026 |
| Aaron James Laurita | Chief Financial Officer | 26,357 | Apr 30, 2026 |
| Paul Hopper | Director | 147,721,428 | May 6, 2026 |
| Ian Lawrence Turner | Director | 9,985,292 | Apr 1, 2026 |
| Noel Donnelly | Director | – | Apr 1, 2026 |
| Hester Denise Larkin | Director | 644,247 | Mar 31, 2026 |
| Bruce Michael Goodwin | Director | – | Mar 18, 2026 |